Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weight loss drug shows promise in early trial

NCT ID NCT06124807

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called Mazdutide to help adults with obesity or overweight lose weight. 179 participants took either the drug or a placebo for about 62 weeks. The main goal was to see how much weight they lost after 32 weeks, with a focus on safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

179 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: W8M-MC-OXA1: * Are males and females who agree to abide by the reproductive and contraceptive requirements W8M-MC-CWMM: * Have a BMI ≥27 kilograms per square meter (kg/m²) Exclusion Criteria: W8M-MC-OXA1: * Have any prior diagnosis of diabetes mellitus, that is type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus, except gestational diabetes. * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure (CHF). * Have a history of New York Heart Association (NYHA) Functional Classification I-IV CHF. * Participants with hypertension who do not have well-controlled blood pressure (BP) (\>140/90 mmHg), regardless of antihypertensive treatment. Participants receiving treatment for hypertension should be on a stable antihypertensive regimen for at least 3 months prior to screening. * Have a history of acute or chronic pancreatitis. Note: If the investigator anticipates a need to add antihypertensive medication during the study, the participant should not be included in the ambulatory blood pressure monitoring (ABPM) procedures. CWMM: * Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have a history of symptomatic gallbladder disease within the past 2 years. * Have a lifetime history of suicide attempts.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder overnutrition Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight and obesity

Contacts and locations

Locations

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212, United States

  • Central Washington Health Services Association d/b/a Confluence Health

    Wenatchee, Washington, 98801, United States

  • Charter Research - Lady Lake

    The Villages, Florida, 32162, United States

  • Charter Research - Winter Park

    Orlando, Florida, 32803, United States

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas, 66606, United States

  • Dent Neurologic Institute

    Amherst, New York, 14226, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Great Lakes Clinical Trials - Andersonville

    Chicago, Illinois, 60640, United States

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, Illinois, 60640, United States

  • Headlands Research - Scottsdale

    Scottsdale, Arizona, 85260, United States

  • IMA Clinical Research Austin

    Austin, Texas, 78745, United States

  • Knownwell

    Needham, Massachusetts, 02492, United States

  • L-MARC Research Center

    Louisville, Kentucky, 40213, United States

  • Las Vegas Medical Research

    Las Vegas, Nevada, 89128, United States

  • Lucas Research, Inc.

    New Bern, North Carolina, 28562, United States

  • North Suffolk Neurology

    Port Jefferson Station, New York, 11776, United States

  • Northeast Research Institute (NERI)

    Fleming Island, Florida, 32003, United States

  • Pacific Diabetes & Endocrine Center

    Honolulu, Hawaii, 96817, United States

  • Peninsula Research Associates

    Rolling Hills Estates, California, 90274, United States

  • PlanIt Research, PLLC

    Houston, Texas, 77079, United States

  • Quality Medical Research

    Nashville, Tennessee, 37211, United States

  • Spectrum Medical, Inc.

    Danville, Virginia, 24541, United States

  • StudyMetrix Research

    City of Saint Peters, Missouri, 63303, United States

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida, 34652, United States

  • Tekton Research - Fredericksburg Road

    San Antonio, Texas, 78229, United States

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa

    Chandler, Arizona, 85225, United States

  • The Institute for Liver Health II dba Arizona Liver Health-Tucson

    Tucson, Arizona, 85712, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research, Huntington Park

    Huntington Park, California, 90255, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.